Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Venous ulcer Stories

2010-03-23 09:34:00

ADDISON, Texas, March 23 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) announced that it sponsored a Wound Dressing Workshop at the 2010 Diabetic Foot Global Conference. Attendees of the Diabetic Foot Global Conference (DFCon) in Hollywood, California on March 20, 2010 participated in a hands-on workshop where they were trained in "best clinical practice" for Altrazeal(TM). Participants learned application techniques, clinical endpoints, and methods for treating different wound...

2010-02-18 12:22:00

BOSTON, Feb. 18 /PRNewswire/ -- TEI Biosciences Inc. announced today that its PriMatrix(TM) Dermal Repair Scaffold has been awarded the coveted American Podiatric Medical Association's (APMA) Seal of Approval. PriMatrix is a bioactive collagen matrix used in the management of diabetic and venous ulcers, second-degree burns, and surgical and trauma wounds. APMA is the nation's leading professional society for foot and ankle specialists. The Seal of Approval Program was created to inform...

2010-02-11 07:00:00

ROCKVILLE, Md., Feb. 11 /PRNewswire/ -- Glycotex, Inc. today announced the expansion of its patent portfolio in Advanced Wound Healing for its product candidate GLYC-101 currently in clinical phase 2 in the United States. On January 19, 2010 US Patent No. 7,648,968 issued with claims directed to the use of microparticulate glucan including GLYC-101 for the treatment of dermal ulcers. The grant of this US patent represents a significant development in Glycotex's US patent portfolio as it...

2010-01-13 18:35:00

FORT WORTH, Texas, Jan. 13 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is nearing the completion of its registration of CellerateRX in Mexico and has identified its first distributor in that country. Numerous physicians in the nation have already evaluated the Activated Collagen wound care product and were impressed with its speed and efficacy in the management of diabetic ulcers and are optimistic that it will play a...

2009-12-22 08:17:00

RICHMOND, Virginia and ROSH HA'AYIN, Israel, December 22 /PRNewswire/ -- EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for advanced chronic wound management, announced today that it successfully completed its latest round of funding of US $2.5 million. The round was led by Eli Gilboa, CPA, of Gilboa & Licht, who serves as the company's active chairman at a company valuation of US$18.5 million. To date, the company has raised a total US$10 million. Proceeds will be...

2009-12-16 11:10:00

SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on recent clinical findings published in the December issue of Diabetes Care showing an increase in mortality in diabetic patients with a history of foot ulcer (HFU) compared with diabetic patients without HFU and with non-diabetic patients. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ) The study titled, "A history of foot ulcer increases mortality among persons with...

2009-12-14 08:15:00

SAN DIEGO, Dec. 14 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced a presentation titled, "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic Ulcers," at the Tenth Annual Wound Healing: Science and Industry Conference held December 10-13, 2009 in St. Thomas, U.S. Virgin Islands. The conference is attended by top industry leaders and renowned researchers in the field of advanced wound healing. Dr. Barbara K. Sosnowski, Cardium's Vice...

2009-12-03 09:50:00

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that its wholly-owned subsidiary, Tissue Repair Company, submitted a 510(k) premarket notification filing with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its Excellagen(TM) product candidate based on positive data from the Company's recently completed Phase 2b Matrix clinical study. Today's submission with the FDA covers ExcellagenXL(TM) and ExcellagenFX(TM),...

2009-11-19 06:30:00

ST. PETERSBURG, Fla., Nov. 19 /PRNewswire-FirstCall/ -- The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc (LSE: SN; NYSE: SNN), supports the American Medical Association's creation of the new Category (1) Current Procedural Terminology (CPT) Code 29581, "Application of multi-layer venous wound compression system, below knee." The new code goes into effect on January 1, 2010. "Venous leg ulcers afflict approximately one percent of...

2009-11-03 07:45:00

FORT WORTH, Texas, Nov. 3 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM), announced today that a clinical study, "Activated Collagen Accelerates Wound Repair and Modulates Cytokine Production in Whole Blood and PBMC Cultures" was presented at the Tri-Society Annual Conference 2009 of the Society for Leukocyte Biology, International Cytokine Society, & International Society for Interferon and Cytokine Research, Cellular...